Inhibition of SARS Coronavirus Infection in Vitro with Clinically Approved Antiviral Drugs

10.3201/eid1004.030458

Saved in:

Bibliographic Details
Main Authors:	Tan, E.L.C, Ooi, E.E, Lin, C.-Y, Tan, H.C, Ling, A.E, Lim, B, Stanton, L.W
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	Centers for Disease Control and Prevention (CDC) 2020
Subjects:	aciclovir alpha interferon alphan1 interferon alphan3 interferon amantadine antivirus agent beta1a interferon foscarnet sodium ganciclovir human leukocyte interferon alpha indinavir interferon beta serine lamivudine multiferon nelfinavir nucleoside analog oseltamivir proteinase inhibitor recombinant alpha2a interferon recombinant alpha2b interferon ribavirin RNA directed DNA polymerase inhibitor saquinavir sialidase inhibitor unclassified drug zanamivir zidovudine animal cell antiviral activity article controlled study cytopathogenic effect drug efficacy drug screening in vitro study infection prevention nonhuman SARS coronavirus severe acute respiratory syndrome Vero cell virus culture virus load virus plaque
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/181117
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-181117
record_format	dspace
spelling	sg-nus-scholar.10635-1811172024-04-03T09:51:43Z Inhibition of SARS Coronavirus Infection in Vitro with Clinically Approved Antiviral Drugs Tan, E.L.C Ooi, E.E Lin, C.-Y Tan, H.C Ling, A.E Lim, B Stanton, L.W DUKE-NUS MEDICAL SCHOOL BIOLOGICAL SCIENCES aciclovir alpha interferon alphan1 interferon alphan3 interferon amantadine antivirus agent beta1a interferon foscarnet sodium ganciclovir human leukocyte interferon alpha indinavir interferon beta serine lamivudine multiferon nelfinavir nucleoside analog oseltamivir proteinase inhibitor recombinant alpha2a interferon recombinant alpha2b interferon ribavirin RNA directed DNA polymerase inhibitor saquinavir sialidase inhibitor unclassified drug zanamivir zidovudine animal cell antiviral activity article controlled study cytopathogenic effect drug efficacy drug screening in vitro study infection prevention nonhuman SARS coronavirus severe acute respiratory syndrome Vero cell virus culture virus load virus plaque 10.3201/eid1004.030458 Emerging Infectious Diseases 10 4 581-586 2020-10-27T09:53:42Z 2020-10-27T09:53:42Z 2004 Article Tan, E.L.C, Ooi, E.E, Lin, C.-Y, Tan, H.C, Ling, A.E, Lim, B, Stanton, L.W (2004). Inhibition of SARS Coronavirus Infection in Vitro with Clinically Approved Antiviral Drugs. Emerging Infectious Diseases 10 (4) : 581-586. ScholarBank@NUS Repository. https://doi.org/10.3201/eid1004.030458 10806040 https://scholarbank.nus.edu.sg/handle/10635/181117 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Centers for Disease Control and Prevention (CDC) Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	aciclovir alpha interferon alphan1 interferon alphan3 interferon amantadine antivirus agent beta1a interferon foscarnet sodium ganciclovir human leukocyte interferon alpha indinavir interferon beta serine lamivudine multiferon nelfinavir nucleoside analog oseltamivir proteinase inhibitor recombinant alpha2a interferon recombinant alpha2b interferon ribavirin RNA directed DNA polymerase inhibitor saquinavir sialidase inhibitor unclassified drug zanamivir zidovudine animal cell antiviral activity article controlled study cytopathogenic effect drug efficacy drug screening in vitro study infection prevention nonhuman SARS coronavirus severe acute respiratory syndrome Vero cell virus culture virus load virus plaque
spellingShingle	aciclovir alpha interferon alphan1 interferon alphan3 interferon amantadine antivirus agent beta1a interferon foscarnet sodium ganciclovir human leukocyte interferon alpha indinavir interferon beta serine lamivudine multiferon nelfinavir nucleoside analog oseltamivir proteinase inhibitor recombinant alpha2a interferon recombinant alpha2b interferon ribavirin RNA directed DNA polymerase inhibitor saquinavir sialidase inhibitor unclassified drug zanamivir zidovudine animal cell antiviral activity article controlled study cytopathogenic effect drug efficacy drug screening in vitro study infection prevention nonhuman SARS coronavirus severe acute respiratory syndrome Vero cell virus culture virus load virus plaque Tan, E.L.C Ooi, E.E Lin, C.-Y Tan, H.C Ling, A.E Lim, B Stanton, L.W Inhibition of SARS Coronavirus Infection in Vitro with Clinically Approved Antiviral Drugs
description	10.3201/eid1004.030458
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Tan, E.L.C Ooi, E.E Lin, C.-Y Tan, H.C Ling, A.E Lim, B Stanton, L.W
format	Article
author	Tan, E.L.C Ooi, E.E Lin, C.-Y Tan, H.C Ling, A.E Lim, B Stanton, L.W
author_sort	Tan, E.L.C
title	Inhibition of SARS Coronavirus Infection in Vitro with Clinically Approved Antiviral Drugs
title_short	Inhibition of SARS Coronavirus Infection in Vitro with Clinically Approved Antiviral Drugs
title_full	Inhibition of SARS Coronavirus Infection in Vitro with Clinically Approved Antiviral Drugs
title_fullStr	Inhibition of SARS Coronavirus Infection in Vitro with Clinically Approved Antiviral Drugs
title_full_unstemmed	Inhibition of SARS Coronavirus Infection in Vitro with Clinically Approved Antiviral Drugs
title_sort	inhibition of sars coronavirus infection in vitro with clinically approved antiviral drugs
publisher	Centers for Disease Control and Prevention (CDC)
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/181117
_version_	1795374528366379008

Inhibition of SARS Coronavirus Infection in Vitro with Clinically Approved Antiviral Drugs

Similar Items